Lung cancer incidence rates in the United States have undergone a significant transformation over the last several decades, ...
Though the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal ...
The five-year survival rate for all cancers combined in the US reached a landmark 70% for Americans diagnosed between 2015 ...
An annual report from the American Cancer Society shows that, for the first time, over 70% of Americans diagnosed with cancer ...
Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...
Five-year relative survival rates for all cancers combined have increased to 70% for people diagnosed during 2015 to 2021 in ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Pancreatic Cancer Action Network Calls for Immediate, Sustained Investment in Research Toward Early Detection and Treatment ...
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
News-Medical.Net on MSN
Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback